Intraoperative radiotherapy (IORT) as a boost in patients with early-stage breast cancer

• Verfasst von: Kraus-Tiefenbacher, Uta [VerfasserIn]
• Verfasst von: Bauer, Lelia [VerfasserIn]
• Verfasst von: Kehrer, Tanja [VerfasserIn]
• Verfasst von: Hermann, Brigitte [VerfasserIn]
• Verfasst von: Melchert, Frank [VerfasserIn]
• Verfasst von: Wenz, Frederik [VerfasserIn]
• Titel: Intraoperative radiotherapy (IORT) as a boost in patients with early-stage breast cancer
• Titelzusatz: acute toxicity
• Verf.angabe: Uta Kraus-Tiefenbacher, Lelia Bauer, Tanja Kehrer, Brigitte Hermann, Frank Melchert, Frederik Wenz
• E-Jahr: 2006
• Jahr: February 14, 2006
• Umfang: 6 S.
• Fussnoten: Gesehen am 25.02.2022
• Titel Quelle: Enthalten in: Onkologie
• Ort Quelle: Basel : Karger, 1978
• Jahr Quelle: 2006
• Band/Heft Quelle: 29(2006), 3, Seite 77-82
• ISSN Quelle: 1423-0240
• DOI: doi:10.1159/000091160
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: 20-year follow-up
• Sach-SW: boost
• Sach-SW: brachytherapy
• Sach-SW: breast cancer
• Sach-SW: conservative surgery
• Sach-SW: conserving surgery
• Sach-SW: cosmetic outcome
• Sach-SW: intraoperative
• Sach-SW: irradiation
• Sach-SW: local recurrence
• Sach-SW: lumpectomy
• Sach-SW: mastectomy
• Sach-SW: radiotherapy
• Sach-SW: targit
• Sach-SW: therapy
• Sach-SW: toxicity, acute
• K10plus-PPN: 1793942110

Abstract

Background: We report on acute toxicities as well as the early cosmetic outcome of patients receiving intraoperative radiotherapy ( IORT) followed by whole-breast radiotherapy ( WBRT) compared to patients treated with standard WBRT alone. Patients and Methods: From 2/2002 until 2/2005, 84 breast cancer patients were treated with IORT during breast-conserving surgery ( BCS) as a boost ( 20 Gy/50 kV X-rays) followed by WBRT. After wound healing, all IORT patients were treated with WBRT at a total dose of 46 Gy. For the purpose of comparison, 53 patients treated consecutively between 1/2003 and 12/2004 in our institution with BCS followed by WBRT at a total dose of 50-66 Gy, were analyzed. All patients had a defined follow-up schedule. Toxicities were prospectively documented using the CTC/EORTC Score. Cosmesis was evaluated after 6 months using a 1-4 score. Results: Treatment was well tolerated with no grade 3/4 acute toxicity. Rare adverse effects following IORT included wound healing problems ( 2%), erythema grade I-II ( 3%), palpable seroma ( 6%) and mastitis ( 2-4%). The number of patients with induration of the tumor bed was comparably low. Conclusion: IORT with the Intrabeam (TM) system applied as a boost during BCS, followed by 46 Gy WBRT, exerts similar acute toxicity as standard WBRT. Further follow-up is needed to assess long-term toxicity and efficacy.